Breaking News

ARCA, DCRI in AF Clinical Trial Agreement

To execute Phase IIb/III of Gencaro in atrial fibrillation

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ARCA biopharma and Duke University’s Duke Clinical Research Institute (DCRI), have entered an agreement under which ARCA and the DCRI will work together to execute GENETIC-AF, a Phase IIb/III genetically-targeted, comparative effectiveness clinical trial evaluating Gencaro (bucindolol hydrochloride) as a potential treatment for the prevention of atrial fibrillation (AF) in patients with heart failure.
 
ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted therapy for the prevention of AF. Patient enrollment is expected to begin 1Q14. DCRI will serve as the coordinating center and principal investigator for GENETIC-AF.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters